Perifosine

Early Results of Phase 2 Trial of Perifosine (KRX-0401) for the Treatment of Recurrent Malignant Gliomas Presented at the 12th Annual Scientific Meeting of Society for Neuro-Oncology

Poster presentation highlights response rate in subset of patients with Anaplastic Gliomas NEW YORK, Nov. 19 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today announced that early results of a phase II single agent trial of perifosine (KR...

Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Multiple Myeloma

...domized Study to Assess the Efficacy and Safety of perifosine Added to the Combination of Bortezomib and Dexamet...ng multiple myeloma centers, are encouraged to see perifosine move into this final stage of testing, and look fo...ive data and our favorable experience overall with perifosine in this setting, we are hopeful that the upcoming ...

U-M researchers link pathway to breast cancer stem cells

... the Akt pathway. Tumors in mice were treated with perifosine or docetaxel, a standard chemotherapy drug. The do...mber of cancer stem cells in the tumor. But adding perifosine reduced the cancer stem cell population by up to 90 percent. What's more, the cells treated with perifosine either with or without docetaxel were less likel...

AEterna Zentaris Reports First Quarter 2009 Financial and Operating Results

...ill push forward our promising drug candidates in oncology, such as AEZS-108 and AEZS-112, while in collaboration with our partners, we expect to move perifosine and ozarelix to the final development stages." Dennis Turpin, Senior Vice President and Chief Financial Officer of AEterna Zentaris added, "The rece...

Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results

...ter, Michael S. Weiss, Keryx's Chairman and Chief Executive Officer, said, "During the third quarter, we continued to make progress in our Zerenex and perifosine clinical programs, while operating with a lean overhead structure." Weiss continued, "We expect our cash burn to be approximately $3 million for the r...

Keryx Biopharmaceuticals' KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology

... Paul Richardson, MD commented, "The addition of perifosine to bortezomib, with or without dexamethasone, has ...tle: Phase I/II Results of a Multicenter Trial of perifosine (KRX-0401) + Bortezomib in Patients with Relapsed... a Phase II Trial of the Novel Oral Akt Inhibitor perifosine in Relapsed and/or Refractory Waldenstrom Macroglo...

Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results

...We believe that the resulting organization, while lean, possesses the requisite strengths and capabilities necessary to expeditiously move Zerenex and perifosine forward, as well as to assess additional opportunities which may enhance our product pipeline." Weiss continued, "With respect to our financial health...

Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia

... Data on perifosine in the Treatment of Patients with Relapsed/Refract...4] - Board #318-I Multi-Center Phase II Study of perifosine (KRX-0401) Alone and in Combination with Dexametha...rch Consortium (MMRC) Multicenter Phase I Trial of perifosine (KRX-0401) in Combination with Lenalidomide and De...

Perifosine in Medical Technology

Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium

Oral Presentation by Dr. Robert Figlin Highlights Phase 2 Data Showing 31% Partial Response Rate and a 62% Overall Clinical Benefit Rate to Perifosine Used as a Single Agent and Phase 1 Data Showing No Evidence of Increased Toxicity When Combined with Sorafenib NEW YORK, Nov. ...

AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting

Results showed an overall CBR of 52% which compares favorably with the activity of mTOR inhibitors QUEBEC CITY, QC, June 04, 2007 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. , a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that its partner, Keryx B...

Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center

...the process of finalizing late-stage protocols for perifosine in the treatment of Multiple Myeloma and Metastati...al Cancer Institute demonstrated that single agent perifosine not only induced tumor regression and delayed tumor growth, but that perifosine also improved the survival of mice bearing neurobl...

Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer

...act #4081, entitled, "Randomized phase II study of perifosine in combination with capecitabine versus capecitabi...650 mg/m2) on days 1-14 every 21 days, plus either perifosine or placebo at 50 mg daily. Treatment was continue...le for response (20 patients on the capecitabine + perifosine arm and 15 patients on the capecitabine + placebo ...

Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer

...act #4081, entitled, "Randomized phase II study of perifosine in combination with capecitabine versus capecitabi...0 mg/m2) on days 1 - 14 every 21 days, plus either perifosine or placebo at 50 mg daily. Treatment was continue...le for response (20 patients on the capecitabine + perifosine arm and 15 patients on the capecitabine + placebo ...

Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401's Activity in the Treatment of Advanced Metastatic Renal Cell Cancer

...oma. Abstract #5034, entitled, "Phase II study of perifosine in metastatic renal cell carcinoma (RCC) progressi...r inhibitor (sunitinib or sorafenib). Safety of perifosine in this patient population was evaluated as a secondary endpoint. Best response to single agent perifosine was as follows: Group N PR ...

Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting

...se 1/2 Study Evaluating the Safety and Efficacy of perifosine (KRX-0401) + Bortezomib (VELCADE(R)) in Patients w...le disease (no progression for 3 months) to either perifosine + bortezomib (+/-dexamethasone) for patients previ...ed, "We believe these data confirm the activity of perifosine both in patients who have relapsed following borte...

Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology

...resents combined results from a Phase 1/2 study of perifosine in combination with bortezomib (+/- dexamethasone)...) today announced data on the clinical activity of perifosine (KRX-0401) in combination with bortezomib (+/- dex...se 1/2 Study Evaluating the Safety and Efficacy of perifosine (KRX-0401) + Bortezomib (VELCADE(R)) in Patients w...

Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology

...emonstrating the single agent clinical activity of perifosine in patients with relapsed / refractory Waldenstr...2 results on the single agent clinical activity of perifosine in patients with both relapsed and/or refractory W.... All patients were scheduled to receive 150 mg of perifosine daily in a 28 day cycle for at least 6 cycles. Tox...

Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois

... Phase 2 Results of perifosine in the Treatment of Patients with Relapsed/Refrac...ly: Abstract 16024: Phase 1 multicenter trial of perifosine in combination with sorafenib for patients with ad... differentiation and cell survival. The effects of perifosine on Akt are of particular interest because of the i...

Perifosine in Biological Technology

AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma

QUEBEC CITY, Aug. 3 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS , TSX: AEZ), ("the Company") a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ), its partner and licensee for perifosi...

AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer

QUEBEC CITY, June 8 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS , TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today disclosed preliminary results for the Company's European multi-center Phase 2 trial in non-small cell lung cancer (NSC...

Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results

...oth our compounds, regained full compliance with the listing requirements of the Nasdaq Capital Market, and announced our SPA for the Phase 3 trial of perifosine in multiple myeloma. We look forward to finalizing our discussions with the FDA regarding the U.S. Phase 3 program for Zerenex shortly, at which time...

AEterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting

... Partner Keryx to present Phase 2 data on perifosine for multiple cancers QUEBEC CITY, May 19 /PR...r Session: 2 pm - 6 pm (Level 2, West Hall C) perifosine Additionally, AEterna Zentaris' partner, Kery...ng the ASCO meeting. Keryx is currently developing perifosine in multiple Phase 2 trials for various types of ca...

Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology

... th , 2009: #5034: Phase II study of perifosine in metastatic renal cell carcinoma (RCC) progressi... st , 2009: #5101: A phase II trial of perifosine in patients with advanced renal cell carcinoma (RC..., 2009: #4081: Randomized phase II study of perifosine in combination with capecitabine versus capecitabi...

Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research

... studies in neuroblastoma cell lines indicate that perifosine treatment induced inhibition of Akt phosphorylatio...nd decreases of cell survival. In vivo studies of perifosine treatment led to significant increases in neurobla...de that the data indicates that as a single agent, perifosine targets activation of Akt in neuroblastoma cells a...

AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results

... while license revenues witnessed a decrease due to the non-recurrence in 2008 of milestone payments received from one of our partners, related to the perifosine Phase 2 trials. Consolidated selling, general and administrative ("SG&A") expenses were $3.0 million for the quarter ended December 31, 2008, co...

Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results

...nce I joined back in 2002. However, with the restructuring now substantially complete, I believe that Keryx is now well-positioned to move Zerenex and perifosine forward through advanced clinical development." Weiss continued, "On the financial side, with respect to our strategic licensing arrangement for Zeren...

Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan

... a KRX-0401 (perifosine) Phase 3 trial until additional data are accumulated and analyses are completed from on-going exploratory studies of perifosine as a treatment for the following tumor types: renal cell, colon, hepatocellular, multiple myeloma, waldenstrom's macroglobulinemia and sarco...

Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint

...rapidly moving Zerenex forward for ESRD patients with hyperphosphatemia and perifosine forward for cancer. Our goal is to have perifosine in a pivotal program this year and be well into our Zerenex high- dose Phas...